<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38310465</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-5576</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Current cancer drug targets</Title><ISOAbbreviation>Curr Cancer Drug Targets</ISOAbbreviation></Journal><ArticleTitle>The Effects of Mesenchymal Stem Cells Loaded with Oncolytic <i>Coxsackievirus A21</i> on Mouse Models of Colorectal Cancer.</ArticleTitle><Pagination><StartPage>967</StartPage><EndPage>974</EndPage><MedlinePgn>967-974</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/0115680096273465231201115839</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer is a major cause of death worldwide. Colorectal cancer is the second most common type. Additional treatments like chemotherapy and radiation therapy may be recommended. Developing new techniques is vital due to drug resistance and a lack of targeted therapies.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this study, the effects of mesenchymal stem cells (MSCs) loaded with oncolytic <i>Coxsackievirus A21</i> (CVA21) on a mouse model of CRC were investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The therapeutic potency of MSCs loaded with oncolytic CVA21 were evaluated in an experimental mouse model of colorectal cancer which received an injection CT26 cells per mouse subcutaneously. Splenocyte proliferation index, lactate dehydrogenase (LDH) assay, nitric oxide (NO) production assessment, and cytokine assay (IFN-γ, IL-4, IL-10, and TGF-β) in the splenocyte supernatant were all used to evaluate the impact of MSCs loaded with CVA21.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results of this study showed that the treatment of a mouse model of colorectal cancer with MSCs loaded with oncolytic CVA21 could significantly suppress the tumor growth, which was accompanied by stimulation of splenocytes proliferation index, an increase of NO and LDH. Also, MSCs loaded with oncolytic CVA21 increased the secretion of IFN-γ and decreased the secretion of IL-4, IL-10, and TGF-β.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of the current study suggest that MSCs loaded with oncolytic CVA21 therapy for the CRC mouse model may have some potential advantages. On the other hand, the results of the study showed that, in addition to activating the acquired immune system, the use of MSCs loaded with oncolytic CVA21 also stimulates the innate immune system by increasing level of nitric oxide.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karbalaee</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehdizadeh</LastName><ForeName>Saber</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4433-0162</Identifier><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaleh</LastName><ForeName>Hadi Esmaeili Gouvarchin</ForeName><Initials>HEG</Initials><AffiliationInfo><Affiliation>Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izadi</LastName><ForeName>Morteza</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2046-6321</Identifier><AffiliationInfo><Affiliation>Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondori</LastName><ForeName>Bahman Jalali</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorostkar</LastName><ForeName>Ruhollah</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Seyed Morteza</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-9987-3829</Identifier><AffiliationInfo><Affiliation>Medicine, Quran and Hadith Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Cancer Drug Targets</MedlineTA><NlmUniqueID>101094211</NlmUniqueID><ISSNLinking>1568-0096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="N">Oncolytic Virotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="N">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-tumor immunity</Keyword><Keyword MajorTopicYN="N">CT26 cell line</Keyword><Keyword MajorTopicYN="N">Coxsackievirus A21</Keyword><Keyword MajorTopicYN="N">colorectal cancer</Keyword><Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword><Keyword MajorTopicYN="N">oncolytic virus.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>4</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38310465</ArticleId><ArticleId IdType="doi">10.2174/0115680096273465231201115839</ArticleId><ArticleId IdType="pii">CCDT-EPUB-137799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferlay J.; Colombet M.; Soerjomataram I.; Mathers C.; Parkin D.M.; Piñeros M.; Znaor A.; Bray F.; Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019,144(8),1941-1953</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.31937</ArticleId><ArticleId IdType="pubmed">30350310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2020,70(4),313-313</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L.; Eng C.; Nieman L.Z.; Kapadia A.S.; Du X.L.; Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011,34(6),573-580</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COC.0b013e3181fe41ed</ArticleId><ArticleId IdType="pubmed">21217399</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2018. CA Cancer J Clin 2018,68(1),7-30</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21442</ArticleId><ArticleId IdType="pubmed">29313949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey C.E.; Hu C.Y.; You Y.N.; Bednarski B.K.; Rodriguez-Bigas M.A.; Skibber J.M.; Cantor S.B.; Chang G.J.; Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015,150(1),17-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2014.1756</ArticleId><ArticleId IdType="pubmed">25372703</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanikachalam K.; Khan G.; Colorectal cancer and nutrition. Nutrients 2019,11(1),164</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11010164</ArticleId><ArticleId IdType="pubmed">30646512</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold M.; Sierra M.S.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017,66(4),683-691</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-310912</ArticleId><ArticleId IdType="pubmed">26818619</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolatkhah R.; Colorectal cancer in Iran: Molecular epidemiology and screening strategies. J Cancer Epidemiol 2015,2015</Citation></Reference><Reference><Citation>Johdi N.A.; Sukor N.F.; Colorectal cancer immunotherapy: Options and strategies. Front Immunol 2020,11,1624</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01624</ArticleId><ArticleId IdType="pubmed">33042104</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarti S.; Peterson C.Y.; Sriram D.; Mahipal A.; Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol 2020,12(8),808-832</Citation><ArticleIdList><ArticleId IdType="doi">10.4251/wjgo.v12.i8.808</ArticleId><ArticleId IdType="pubmed">32879661</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasteva N.; Georgieva M.; Promising therapeutic strategies for colorectal cancer treatment based on nanomaterials. Pharmaceutics 2022,14(6),1213</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14061213</ArticleId><ArticleId IdType="pubmed">35745786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooti W.; Oncolytic Newcastle disease virus effects on immune response-a new issue in cancer treatment. Klin Onkol 2023,36(2),124-129</Citation><ArticleIdList><ArticleId IdType="doi">10.48095/ccko2023124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley S.; Jakes A.; Harrington K.; Pandha H.; Melcher A.; Errington-Mais F.; Applications of coxsackievirus A21 in oncology. Oncolytic Virother 2014,3,47-55</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S56322</ArticleId><ArticleId IdType="pubmed">27512662</ArticleId></ArticleIdList></Reference><Reference><Citation>Annels N.E.; Arif M.; Simpson G.R.; Denyer M.; Moller-Levet C.; Mansfield D.; Butler R.; Shafren D.; Au G.; Knowles M.; Harrington K.; Vile R.; Melcher A.; Pandha H.; Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus. Mol Ther Oncolytics 2018,9,1-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2018.02.001</ArticleId><ArticleId IdType="pubmed">29989024</ArticleId></ArticleIdList></Reference><Reference><Citation>Moaven O.; Mangieri C.W.; Stauffer J.A.; Anastasiadis P.Z.; Borad M.J.; Strategies to develop potent oncolytic viruses and enhance their therapeutic efficacy. JCO Precis Oncol 2021,5(5),733-743</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.21.00003</ArticleId><ArticleId IdType="pubmed">34250395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.; Zhao X.; He Z.; Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy (Review). Oncol Lett 2021,21(4),238</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2021.12499</ArticleId><ArticleId IdType="pubmed">33664802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahasa K.J.; de Pillis L.; Ouifki R.; Eladdadi A.; Maini P.; Yoon A.R.; Yun C.O.; Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci Rep 2020,10(1),425</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-57240-x</ArticleId><ArticleId IdType="pubmed">31949228</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon A.R.; Rivera-Cruz C.; Gimble J.M.; Yun C.O.; Figueiredo M.L.; Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors. Mol Ther Oncolytics 2022,25,78-97</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2022.03.008</ArticleId><ArticleId IdType="pubmed">35434272</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi Darestani N.; Gilmanova A.I.; Al-Gazally M.E.; Zekiy A.O.; Ansari M.J.; Zabibah R.S.; Jawad M.A.; Al-Shalah S.A.J.; Rizaev J.A.; Alnassar Y.S.; Mohammed N.M.; Mustafa Y.F.; Darvishi M.; Akhavan-Sigari R.; Mesenchymal stem cell-released oncolytic virus: Asn innovative strategy for cancer treatment. Cell Commun Signal 2023,21(1),43</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-022-01012-0</ArticleId><ArticleId IdType="pubmed">36829187</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaili Gourvarchin Galeh H.; Meysam Abtahi Froushani S.; Afzale Ahangaran N.; Hadai S.N.; Effects of educated monocytes with xenogeneic mesenchymal stem cell–derived conditioned medium in a mouse model of chronic asthma. Immunol Invest 2018,47(5),504-520</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2018.1458108</ArticleId><ArticleId IdType="pubmed">29671652</ArticleId></ArticleIdList></Reference><Reference><Citation>Aindelis G.; Tiptiri-Kourpeti A.; Lampri E.; Spyridopoulou K.; Lamprianidou E.; Kotsianidis I.; Ypsilantis P.; Pappa A.; Chlichlia K.; Immune responses raised in an experimental colon carcinoma model following oral administration of Lactobacillus casei. Cancers 2020,12(2),368</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12020368</ArticleId><ArticleId IdType="pubmed">32033490</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarz M.; Ebrahimzadeh M.S.; Miri S.M.; Dianat-Moghadam H.; Ghorbanhosseini S.S.; Mohebbi S.R.; Keyvani H.; Ghaemi A.; Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Virol J 2020,17(1),64</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-020-01326-w</ArticleId><ArticleId IdType="pubmed">31906972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari S.; Froushani S.M.A.; Tokmachi A.; Combined extract of heated 4T1 and a heat-killed preparation of Lactobacillus casei in a mouse model of breast cancer. Iran J Med Sci 2017,42(5),457-464</Citation><ArticleIdList><ArticleId IdType="pubmed">29234178</ArticleId></ArticleIdList></Reference><Reference><Citation>Altun İ.; Sonkaya A.; The most common side effects experienced by patients were receiving first cycle of chemotherapy. Iran J Public Health 2018,47(8),1218-1219</Citation><ArticleIdList><ArticleId IdType="pubmed">30186799</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y.; Yang J.; Fang J.; Zhou Y.; Candi E.; Wang J.; Hua D.; Shao C.; Shi Y.; The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther 2022,7(1),92</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00932-0</ArticleId><ArticleId IdType="pubmed">35314676</ArticleId></ArticleIdList></Reference><Reference><Citation>Au G.G.; Beagley L.G.; Haley E.S.; Barry R.D.; Shafren D.R.; Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol J 2011,8(1),22</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-22</ArticleId><ArticleId IdType="pubmed">21241513</ArticleId></ArticleIdList></Reference><Reference><Citation>Andtbacka R.H.I.; Curti B.; Daniels G.A.; Hallmeyer S.; Whitman E.D.; Lutzky J.; Spitler L.E.; Zhou K.; Bommareddy P.K.; Grose M.; Wang M.; Wu C.; Kaufman H.L.; Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J Clin Oncol 2021,39(34),3829-3838</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.03246</ArticleId><ArticleId IdType="pubmed">34464163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston J.A.; The Efficacy of Coxsackievirus A21 in Combination with Radiotherapy for the Treatment of Colorectal Cancer 2022</Citation></Reference><Reference><Citation>Au G.; Lindberg A.; Barry R.; Shafren D.; Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 2005,26(6),1471-1476</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.26.6.1471</ArticleId><ArticleId IdType="pubmed">15870858</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren D.R.; Au G.G.; Nguyen T.; Newcombe N.G.; Haley E.S.; Beagley L.; Johansson E.S.; Hersey P.; Barry R.D.; Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21. Clin Cancer Res 2004,10(1),53-60</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-0690-3</ArticleId><ArticleId IdType="pubmed">14734451</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.; Hong J.A.; Choi H.J.; Song J.J.; Enhanced tumor targeting and timely viral release of mesenchymal stem cells/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment. Mol Ther Oncolytics 2022,27,26-47</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2022.09.004</ArticleId><ArticleId IdType="pubmed">36247810</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirlekar B.; Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med 2022,10,20503121211069012</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20503121211069012</ArticleId><ArticleId IdType="pubmed">35096390</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgovanovic D.; Song M.; Wang L.; Zhang Y.; Roles of IFN-γ in tumor progression and regression: A review. Biomark Res 2020,8(1),49</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40364-020-00228-x</ArticleId><ArticleId IdType="pubmed">33005420</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>